Is Post-Viral Illness Only a COVID Thing?
Persistent symptoms four to six weeks after RSV, flu, and COVID ran 21 to 24 percent in 5,740 children. Same rate, three different illnesses.
Photo: Sebastian Schuster / Unsplash
No. Post-viral illness is not specific to COVID, and a 2026 study of 5,740 children is one of the largest to set the three side by side. Researchers checked children four to six weeks after a confirmed RSV, influenza, or SARS-CoV-2 infection. Roughly one in five to one in four was still unwell in every group, so the rates came out close together. The symptoms did not, and which symptoms a child was left with is the part that changes what a clinician does next.
More of this series is at the chronic fatigue hub.
What the study actually compared
Bedir and Demir worked from the records of two Istanbul university hospitals. They pulled every child aged 0 to 18 with a PCR-confirmed respiratory infection between January 2020 and December 2024, which was 8,246 records. PCR, or polymerase chain reaction, is the swab test that names which virus a person actually had. After exclusions, about half of them children with no documented follow-up visit, 5,740 were left: 1,540 with SARS-CoV-2, 2,150 with RSV, and 2,050 with influenza. RSV is respiratory syncytial virus, the winter chest infection that sets babies wheezing.
Follow-up came four to six weeks after diagnosis. Persistent symptoms were recorded in 24.0 percent of the RSV group, 22.0 percent of the SARS-CoV-2 group, and 21.2 percent of the influenza group. That difference is small enough to be chance.
This is a retrospective study: the researchers read notes clinicians had already written rather than running a planned assessment. No standardized symptom questionnaire was used, and that limit applies to every number below.
Same rate, three different illnesses
The overall rates came out within three percentage points of each other, at 21.2 to 24.0 percent. The symptom profiles behind those rates were not close at all.
Among children with lingering SARS-CoV-2 symptoms, fatigue appeared in 46 percent, sleep disturbance in 38 percent, headache in 34 percent, and concentration difficulties in 29 percent. Persistent cough turned up in 11 percent. Among the RSV children still symptomatic, the pattern was close to the reverse: persistent cough in 58 percent of them, wheezing in 47 percent, feeding difficulties in 44 percent, and increased work of breathing in 33 percent. Among the influenza children still symptomatic, fatigue appeared in 41 percent, muscle pain in 38 percent, and prolonged fever in 28 percent.
The paper describes the symptom profiles as markedly different. I'd go a step further and call them three different illnesses sharing one label. Post-viral works as a category, with several illnesses under it. Treating all three as one illness throws away which symptoms each child had, and that's what should guide follow-up.
The age problem, which the authors raise first
The three groups were not the same age. RSV was a cohort of babies, at a median of 10.5 months, whereas the SARS-CoV-2 and influenza groups had medians of 7.4 and 7.2 years. Bedir and Demir raise this near the front of their own discussion, writing that the overall prevalence comparisons are partially confounded by age.
Split by age band, the picture sharpens. Among infants under 12 months, RSV left 28.0 percent with persistent symptoms, against 16.2 percent for SARS-CoV-2 and 18.1 percent for influenza. Among school-aged children over 6, SARS-CoV-2 was highest at 26.0 percent, with influenza at 23.4 percent. The researchers checked whether this age pattern could be a fluke, and concluded that that was unlikely.
One measurement limit belongs here. Headache and trouble concentrating have to be reported by a child old enough to describe them, which the authors list among the study's limitations. The very low neurocognitive numbers in a mostly-infant RSV group are partly an artifact of who could answer the question.
This pattern was described long before 2020
Hickie and colleagues published a prospective cohort in the BMJ in 2006 following 253 people in rural Australia from the point of a confirmed infection. They tracked three unrelated organisms: Epstein-Barr virus, which causes glandular fever or mono; Coxiella burnetii, the bacterium behind Q fever; and Ross River virus. At six months, 29 participants, or 12 percent, had a prolonged illness of disabling fatigue, musculoskeletal pain, neurocognitive difficulty, and mood disturbance, and 28 of them met the formal criteria for chronic fatigue syndrome. The authors described that phenotype as stereotyped and reported that it occurred at a similar incidence after each infection. What predicted it was largely the severity of the acute illness, rather than demographic, psychological, or microbiological factors.
That is mostly adults, at six months, with different pathogens, so it doesn't extend the Istanbul findings. The Istanbul study can't show this on its own, but Hickie's can: the same lingering illness followed three unrelated infections.
I've been seeing this in clinic for years. During medical school, the herpes family viruses, Epstein-Barr and cytomegalovirus, were the main viral drivers I saw. We opened our own clinic in 2020, just as COVID was spreading, and viral-triggered presentations have been far more common since. The pattern looks the same regardless of which virus started it. What I see is an immune challenge leaving the immune system hypervigilant, and it doesn't always settle back down on its own. That is a clinical impression from practice rather than a rate or a mechanism either study measured. If Epstein-Barr is the one in your history, what a reactivation workup actually involves covers the testing side of it.
What this changes, and what it doesn't
This study measured symptom persistence and nothing else. No treatment was tested and no test was validated. Two preventive measures were linked to fewer lingering symptoms: palivizumab, an antibody shot given to some high-risk babies for RSV, and the flu vaccine. The authors treat both as early signals, since only 65 babies got palivizumab and the vaccine analysis didn't account for other differences between the children.
The second caution matters more to me. These were children, seen once, at four to six weeks. An adult who has been unwell for three years is not described anywhere in this data. The authors call their own window a snapshot of the post-acute course rather than a definition of long-term outcomes. Six weeks of recovery and three years of disability are different questions. For the longer-horizon version, the unified model of ME/CFS is a better starting point.
What does change is smaller: if your child is still coughing six weeks after RSV, or still flattened six weeks after flu, that is a documented pattern instead of an oddity. The reasonable question for a clinician is whether those symptoms fit what that virus tends to leave behind.
Some symptoms need same-day assessment. Trouble breathing, chest pain, a baby feeding poorly or working hard to breathe, a fever that returns after it had gone: those are reasons to be seen now rather than to keep reading.
If chronic fatigue is part of your picture, ME/CFS, Reconsidered is an upcoming course on ME/CFS, post-viral fatigue, and pacing. You can join The Weekly Well, our free newsletter, to hear when the course opens.
FAQ
Can the flu cause long-term symptoms like long COVID?
Influenza can leave symptoms that outlast the acute illness. In a 2026 cohort of 5,740 children in Istanbul, 21.2 percent still had a documented symptom four to six weeks after a confirmed influenza infection, compared with 22.0 percent after SARS-CoV-2. The complaints were mostly fatigue, muscle pain, and fever that dragged on past the first week. That is a four to six week window in children, so it doesn't describe an adult who has been unwell for years.
Does RSV cause post-viral symptoms in babies?
In the same cohort, 24.0 percent of children with RSV had persistent symptoms at four to six weeks, and that group was mostly infants. What lingered was respiratory and feeding related: persistent cough in 58 percent of them, wheezing in 47 percent, feeding difficulties in 44 percent. Low blood oxygen during the acute illness was the strongest predictor: those infants had about 2.4 times the odds of persistent symptoms.
Is post-viral fatigue after mono the same thing as long COVID?
They are not established as the same illness, and a recognizable fatigue syndrome after infection was documented long before COVID. A 2006 prospective cohort of 253 people in rural Australia followed infections with Epstein-Barr virus, Q fever, and Ross River virus. At six months, 12 percent had a prolonged illness of disabling fatigue, pain, neurocognitive difficulty, and mood disturbance, and the authors reported it occurred at a similar incidence after each of the three.
Why did the three viruses have such different symptoms?
Partly biology and partly who each virus infects. RSV mostly affects babies, and the Istanbul cohort had a median age of 10.5 months in that group against about 7 years in the other two. The authors stated that their overall comparison is partially confounded by age. Neurocognitive symptoms also need a child old enough to describe them, which makes those figures look artificially low in an infant group.
Should I ask for testing if symptoms are still there weeks later?
That is a conversation with the clinician who knows the history rather than something to settle from a blog post. This study tested no treatment and validated no test, so nothing in it supports a specific panel. What it supports is timing: symptoms still present at four to six weeks are a documented pattern, and which symptoms they are can reasonably change what a clinician looks at next.
References
- 1.
- 2.
